Alantolactone inhibits cell proliferation by interrupting the interaction between Cripto-1 and activin receptor type II A in activin signaling pathway

Journal of Biomolecular Screening

Volumn 16, Issue 5, 2011, Pages 525-535

  Shi, Ying ^a   Bao, Yong Li ^a   Wu, Yin ^a   Yu, Chun Lei ^a   Huang, Yan Xin ^a   Sun, Ying ^a   Zheng, Li Hua ^a   Li, Yu Xin ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

Author keywords

activin signaling; alantolactone; Cripto 1; drug screening; mammalian two hybrid

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR 2; ALANTOLACTONE; ONCOPROTEIN; PROTEIN CRIPTO 1; SMAD3 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ACTIVIN RECEPTORS, TYPE II; ACTIVINS; ADENOCARCINOMA; CELL LINE; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HEK293 CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LACTONES; NEOPLASM PROTEINS; PROTEIN BINDING; SESQUITERPENES, EUDESMANE; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

MAMMALIA;

EID: 79959471528     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057111398486     Document Type: Article

References (29)

1. Wrana J. L., Attisano L., Carcamo J., Zentella A., Doody J., Laiho M., Wang X. F., Massague J.. TGF beta Signals through a Heteromeric Protein Kinase Receptor Complex. Cell. 1992 ; 71: 1003-1014
2. Ramachandran A., Marshall E. S., Love D. R., Baguley B. C., Shelling A. N.. Activin Is a Potent Growth Suppressor of Epithelial Ovarian Cancer Cells. Cancer Lett. 2009 ; 285: 157-165
3. Schulz R., Vogel T., Dressel R., Krieglstein K.. TGF-beta Superfamily Members, ActivinA and TGF-beta1, Induce Apoptosis in Oligodendrocytes by Different Pathways. Cell Tissue Res. 2008 ; 334: 327-338
4. Harrison C. A., Gray P. C., Vale W. W., Robertson D. M.. Antagonists of Activin Signaling: Mechanisms and Potential Biological Applications. Trends Endocrinol. Metab. 2005 ; 16: 73-78 (Pubitemid 40270853)
5. Wrana J. L., Attisano L.. The Smad Pathway. Cytokine Growth Factor Rev. 2000 ; 11: 5-13 (Pubitemid 30169721)
6. Saloman D. S., Bianco C., Ebert A. D., Khan N. I., De Santis M., Normanno N., Wechselberger C., Seno M., Williams K., Sanicola M., et al. The EGF-CFC Family: Novel Epidermal Growth Factor-Related Proteins in Development and Cancer. Endocr. Relat. Cancer. 2000 ; 7: 199-226 (Pubitemid 32172272)
7. Adamson E. D., Minchiotti G., Salomon D. S.. Cripto: A Tumor Growth Factor and More. J. Cell Physiol. 2002 ; 190: 267-278 (Pubitemid 34111967)
8. Bianco C., Strizzi L., Mancino M., Rehman A., Hamada S., Watanabe K., De Luca A., Jones B., Balogh G., et al. Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer. Clin. Cancer Res. 2006 ; 12: 5158-5164 (Pubitemid 44453344)
9. Brandt R., Normanno N., Gullick W. J., Lin J. H., Harkins R., Schneider D., Jones B. W., Ciardiello F., Persico M. G., Armenante F., et al. Identification and Biological Characterization of an Epidermal Growth Factor-Related Protein: Cripto-1. J. Biol. Chem. 1994 ; 269: 17320-17328 (Pubitemid 24204060)
10. Wu Z., Li G., Wu L., Weng D., Li X., Yao K.. Cripto-1 Overexpression Is Involved in the Tumorigenesis of Nasopharyngeal Carcinoma. BMC Cancer. 2009 ; 9: 315
11. Bianco C., Adkins H. B., Wechselberger C., Seno M., Normanno N., De Luca A., Sun Y., Khan N., Kenney N., Ebert A., et al. Cripto-1 Activates Nodal- and ALK4-Dependent and -Independent Signaling Pathways in Mammary Epithelial Cells. Mol. Cell Biol. 2002 ; 22: 2586-2597 (Pubitemid 34262981)
12. Bianco C., Wechselberger C., Ebert A., Khan N. I., Sun Y., Salomon D. S.. Identification of Cripto-1 in Human Milk. Breast Cancer Res. Treat. 2001 ; 66: 1-7 (Pubitemid 32397936)
13. Niemeyer C. C., Persico M. G., Adamson E. D.. Cripto: Roles in Mammary Cell Growth, Survival, Differentiation and Transformation. Cell Death Differ. 1998 ; 5: 440-449 (Pubitemid 28356821)
14. Normanno N., De Luca A., Bianco C., Maiello M. R., Carriero M. V., Rehman A., Wechselberger C., Arra C., Strizzi L., Sanicola M., et al. Cripto-1 Overexpression Leads to Enhanced Invasiveness and Resistance to Anoikis in Human MCF-7 Breast Cancer Cells. J. Cell Physiol. 2004 ; 198: 31-39 (Pubitemid 38120963)
15. Bianco C., Strizzi L., Rehman A., Normanno N., Wechselberger C., Sun Y., Khan N., Hirota M., Adkins H., Williams K., et al. A Nodal- and ALK4-Independent Signaling Pathway Activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res. 2003 ; 63: 1192-1197 (Pubitemid 36348694)
16. Gray P. C., Harrison C. A., Vale W.. Cripto Forms a Complex with Activin and Type II Activin Receptors and Can Block Activin Signaling. Proc. Natl. Acad. Sci. U. S. A. 2003 ; 100: 5193-5198 (Pubitemid 36542681)
17. Gray P. C., Shani G., Aung K., Kelber J., Vale W.. Cripto Binds Transforming Growth Factor beta (TGF-beta) and Inhibits TGF-beta Signaling. Mol. Cell Biol. 2006 ; 26: 9268-9278 (Pubitemid 44904422)
18. Deli A., Kreidl E., Santifaller S., Trotter B., Seir K., Berger W., Schulte-Hermann R., Rodgarkia-Dara C., Grusch M.. Activins and Activin Antagonists in Hepatocellular Carcinoma. World J. Gastroenterol. 2008 ; 14: 1699-1709 (Pubitemid 351493376)
19. Burdette J. E., Jeruss J. S., Kurley S. J., Lee E. J., Woodruff T. K.. Activin A Mediates Growth Inhibition and Cell Cycle Arrest through Smads in Human Breast Cancer Cells. Cancer Res. 2005 ; 65: 7968-7975 (Pubitemid 41297276)
20. Su G. H., Bansal R., Murphy K. M., Montgomery E., Yeo C. J., Hruban R. H., Kern S. E.. ACVR1B (ALK4, Activin Receptor Type 1B) Gene Mutations in Pancreatic Carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2001 ; 98: 3254-3257 (Pubitemid 32220832)
21. Matsuo S. E., Leoni S. G., Colquhoun A., Kimura E. T.. Transforming Growth Factor-beta1 and Activin A Generate Antiproliferative Signaling in Thyroid Cancer Cells. J. Endocrinol. 2006 ; 190: 141-150 (Pubitemid 44161069)
22. Xing P. X., Hu X. F., Pietersz G. A., Hosick H. L., McKenzie I. F.. Cripto: A Novel Target for Antibody-Based Cancer Immunotherapy. Cancer Res. 2004 ; 64: 4018-4023 (Pubitemid 38697318)
23. Pal H. C., Sehar I., Bhushan S., Gupta B. D., Saxena A. K.. Activation of Caspases and Poly (ADP-Ribose) Polymerase Cleavage to Induce Apoptosis in Leukemia HL-60 Cells by Inula racemosa. Toxicol. In Vitro. 2010 ; 24: 1599-1609
24. Konishi T., Shimada Y., Nagao T., Okabe H., Konoshima T.. Antiproliferative Sesquiterpene Lactones from the Roots of Inula helenium. Biol. Pharm. Bull. 2002 ; 25: 1370-1372 (Pubitemid 39663205)
25. Wallace H. M., Fraser A. V.. Polyamine Analogues as Anticancer Drugs. Biochem. Soc. Trans. 2003 ; 31: 393-396 (Pubitemid 36520684)
26. Lawrence N. J., McGown A. T., Nduka J., Hadfield J. A., Pritchard R. G.. Cytotoxic Michael-Type Amine Adducts of alpha-Methylene Lactones Alantolactone and Isoalantolactone. Bioorg. Med. Chem. Lett. 2001 ; 11: 429-431 (Pubitemid 32115864)
27. Moustakas A., Kardassis D.. Regulation of the Human p21/WAF1/Cip1 Promoter in Hepatic Cells by Functional Interactions between Sp1 and Smad Family Members. Proc. Natl. Acad. Sci. U. S. A. 1998 ; 95: 6733-6738 (Pubitemid 28278049)
28. Strizzi L., Abbott D. E., Salomon D. S., Hendrix M. J.. Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle. 2008 ; 7: 1931-1935 (Pubitemid 352030336)
29. Lonardo E., Parish C. L., Ponticelli S., Marasco D., Ribeiro D., Ruvo M., De Falco S., Arenas E., Minchiotti G.. A Small Synthetic Cripto Blocking Peptide Improves Neural Induction, Dopaminergic Differentiation, and Functional Integration of Mouse Embryonic Stem Cells in a Rat Model of Parkinson's Disease. Stem Cells. 2010 ; 28: 1326-1337